ACESION PHARMA ApS
CVR 34083738 · Private limited company (ApS) · Active · High risk
ACESION PHARMA ApS is a Private limited company (ApS), founded on , based in Frederiksberg. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 5.3% over the next 12 months, which is 3.8 times the average for Danish companies. 14 annual reports have been published, of which 1 more than six months after the end of the financial year.
Bankruptcy risk for ACESION PHARMA ApS
3.8 × the average (1.41%) · higher risk than 92% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 34083738
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (14 years)
- Address
- Nordre Fasanvej 215
2000 Frederiksberg - Municipality
- Frederiksberg
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 189.1m
- Employees
- 14 (2018)
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 1 of 14 |
| Missing annual report | No |
| Negative equity | – |
| Equity ratio | – |
| Current ratio | – |
| Moves (last 2 years) | 0 |
| CEO changes in total | 5 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 111 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 |
|---|
Latest annual report: · auditor's statement: No assurance.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 182 | ||
| 1 Jan 2024 – 31 Dec 2024 | 176 | ||
| 1 Jan 2023 – 31 Dec 2023 | 158 | ||
| 1 Jan 2022 – 31 Dec 2022 | 164 | ||
| 1 Jan 2021 – 31 Dec 2021 | 188 | Late | |
| 1 Jan 2020 – 31 Dec 2020 | 165 | ||
| 1 Jan 2019 – 31 Dec 2019 | 162 | ||
| 1 Jan 2018 – 31 Dec 2018 | 113 | ||
| 1 Jan 2017 – 31 Dec 2017 | 162 | ||
| 1 Jan 2016 – 31 Dec 2016 | 149 | ||
| 1 Jan 2015 – 31 Dec 2015 | 132 | ||
| 1 Jan 2014 – 31 Dec 2014 | 119 | ||
| 1 Jan 2013 – 31 Dec 2013 | 146 | ||
| 15 Dec 2011 – 31 Dec 2012 | 121 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Morten Grunnet | ||
| CEO | Jakob Dynnes Hansen | ||
| CEO | Torgeir Vaage | ||
| Board | Jørgen Søberg Petersen | Current | |
| Board | Timothy Michael Shannon | Current | |
| Board | Nik Economopoulos | Current | |
| Board | Benjamin Bruno Thorner | Current | |
| Board | Frank Knudsen | ||
| Board | Morten Grunnet | ||
| Board | Bobby G Soni | ||
| Board | Ingelise Saunders | ||
| Board | Carsten Schou | ||
| Board | Stephan Christgau | ||
| Board | Paul David Goldenheim | ||
| Board | Lars Gredsted | ||
| Board | Georgios Trichas | ||
| Board | Ann Mills-Duggan | ||
| Board | Duan Xiang | ||
| Board | Morten Døssing | ||
| Board | Karen Juo-Lai Chu | ||
| Owner (33%) | Novo Holdings A/S | Current | |
| Owner (20%) | Canaan XII L.P. | Current | |
| Owner (15%) | Alpha Wave Ventures II, LP | Current | |
| Owner (5%) | RMG-KB BioAccess Fund, L.P. | Current | |
| Owner (33%) | Novo Holdings A/S | ||
| Owner (25%) | PreSeed Ventures A/S | ||
| Owner (20%) | Broadview Ventures I LLC | ||
| Owner (20%) | PreSeed Ventures A/S | ||
| Owner (10%) | Broadview Ventures I LLC | ||
| Owner (25%) | The Wellcome Trust Limited as trustee of the Wellcome Trust | ||
| Owner (10%) | PreSeed Ventures A/S | ||
| Owner (5%) | Uddannelses- og Forskningsstyrelsen | ||
| Owner (5%) | Broadview Ventures I LLC | ||
| Owner (20%) | The Wellcome Trust Limited as trustee of the Wellcome Trust | ||
| Owner (33%) | Novo Holdings A/S | ||
| Owner (25%) | The Wellcome Trust Limited as trustee of the Wellcome Trust | ||
| Owner (50%) | Novo Holdings A/S | ||
| Owner (25%) | The Wellcome Trust Limited as trustee of the Wellcome Trust | ||
| Owner (33%) | Novo Holdings A/S | ||
| Owner (5%) | Broadview Ventures I LLC | ||
| Owner (20%) | The Wellcome Trust Limited as trustee of the Wellcome Trust | ||
| Owner (10%) | FC Danishbio Holdings Limited | ||
| Owner (25%) | The Wellcome Trust Limited as trustee of the Wellcome Trust | ||
| Owner (50%) | Novo Holdings A/S | ||
| Owner (5%) | FC Danishbio Holdings Limited | ||
| Owner (67%) | Novo Holdings A/S | ||
| Owner (5%) | The Wellcome Trust Limited as trustee of the Wellcome Trust | ||
| Owner (5%) | FC Inbio Holdings Limited | ||
| Owner (50%) | Novo Holdings A/S | ||
| Owner (15%) | Canaan XII L.P. | ||
| Owner (10%) | Alpha Wave Ventures II, LP | ||
| Owner (50%) | Novo Holdings A/S | ||
| Owner (15%) | Canaan XII L.P. | ||
| Owner (10%) | Alpha Wave Ventures II, LP | ||
| Owner (33%) | Novo Holdings A/S | ||
| Owner (20%) | Canaan XII L.P. | ||
| Owner (15%) | Alpha Wave Ventures II, LP | ||
| Owner (5%) | RMG-KB BioAccess Fund, L.P. | ||
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Auditor | PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab | ||
| Founder | Ulrik Svane Sørensen | Current | |
| Founder | Morten Grunnet | Current | |
| Founder | PreSeed Ventures A/S | Current | |
| Founder | Novo Holdings A/S | Current | |
| Founder | SEED CAPITAL DENMARK II K/S | Current |
The CEOs' other companies
Morten Grunnet – 1 other companies
- Grunnet ApS Opløst
Jakob Dynnes Hansen – 5 other companies
- Asarina Pharma ApS Opløst
- BETACURE HOLDING A/S Fusioneret
- Dispersome IP ApS Active
- EVOLVA BIOTECH A/S Opløst
- EVOLVA BIOTECH A/S Fusioneret
Address history (2 moves)
| Nordre Fasanvej 215, 2000 Frederiksberg | |
| Ole Maaløes Vej 3, 2200 København N | |
| c/o NeuroSearch, Pederstrupvej 93, 2750 Ballerup |
Employees per year
Other companies at the same address
- Nordetect ApS Bankrupt
- AdaptVac ApS Active
- Adcendo ApS Active
- Akylox Therapeutics ApS Active
- Antraka ApS Opløst
- Augustine Therapeutics Denmark ApS Active
- Autocert ApS Active
- Avancert ApS Active
- B4C ApS Active
- BOOST Pharma ApS Active
- Baekmark IP Consult ApS Active
- Betula Capital ApS Active
- BioPhenyx ApS Active
- Biobridge Partners ApS Active
- Biotinia ApS Active
- CMCAssist ApS Active
- CMCGreenhouse ApS Active
- CMCHoldings ApS Active
- CaMaRa ApS Active
- Catalyst Vaccination A/S Active
- Chris Cording Jønsson Holding ApS Active
- DARERL ApS Active
- DFY ApS Active
- DeltaBot ApS Active
- Details ApS Active
Similar companies in Frederiksberg
- Koblano Therapeutics ApS Frederiksberg
- Eygo Bio ApS Frederiksberg
- LumenAR ApS Frederiksberg
- IDTA ApS Frederiksberg
- Valicentra ApS Frederiksberg
- Silvics ApS Frederiksberg
- InLife Research ApS Frederiksberg
- NordicRWE Denmark ApS Frederiksberg C
- CaMaRa ApS Frederiksberg
- Hvidberg Compliance Management Aps Frederiksberg
- Vibraint ApS Frederiksberg
- Augustine Therapeutics Denmark ApS Frederiksberg
Questions and answers about ACESION PHARMA ApS
Has ACESION PHARMA ApS gone bankrupt?
No, ACESION PHARMA ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of ACESION PHARMA ApS?
Our model estimates a bankruptcy risk of 5.3% over the next 12 months (high risk), which is 3.8 times the average for Danish companies.
Who is the auditor of ACESION PHARMA ApS?
ACESION PHARMA ApS most recently used EY Godkendt Revisionspartnerselskab.
When was ACESION PHARMA ApS founded?
ACESION PHARMA ApS was founded on 15 December 2011.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.